Sfoglia per Autore
Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.
2005-01-01 Palumbo A; Bringhen S; Musto P; Caravita T; Capozzi R; Callea V; Cangialosi C; Montanaro M; Catalano L; Grasso M; Petti MC; Merla M; Falchi L; Omedè P; Ceccarelli M; Ambrosini MT; Avonto I; Gay F; Falco P; Boccadoro M
VelcadeTM Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.
2005-01-01 Palumbo A; Ambrosini MT; Pregno P; Pescosta N; Callea V; Cangialosi C; Caravita T; Morabito F; Omedè P; Gay F; Avonto I; Falco P; Bringhen S; Boccadoro M
Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.
2005-01-01 Palumbo A; Falco P; Musto P; Corradini P; Di Raimondo R; Rossi G; Giuliani N; Morabito F; Luraschi A; Falcone A; Omedè P; Gay F; Avonto I; Ambrosini MT; Bringhen S; Zeldis J; Knight R; Boccadoro M; Petrucci MT
Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.
2006-01-01 Antonio Palumbo; Sara Bringhen; Patrizia Falco; Cecilia Rus; Federica Cavallo; Maria Teresa Ambrosini; Ilaria Avonto; Francesca Gay; Gabriele Gallone; Tommaso Caravita; Benedetto Bruno; and Mario Boccadoro
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma
2006-01-01 PALUMBO A; AVONTO I; BRUNO B; FALCONE A; SCALZULLI PR; AMBROSINI MT; BRINGHEN S; GAY F; RUS C; CAVALLO F; FALCO P; MASSAIA M; MUSTO P; BOCCADORO M
INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA
2006-01-01 P. Musto; I. Avonto; P.R. Scalzulli; B. Bruno; A. Falcone; M.T. Ambrosini; S. Bringhen; F. Gay; C. Rus; F. Cavallo; P. Falco; M. Massaia; M. Boccadoro; A. Palumbo
New treatment strategies for elderly myeloma patients
2006-01-01 Palumbo A.; Falco P.; Musto P.; Rossi G.; Giuliani N.; Morabito F.; Falcone A.; Gay F.; Avonto I.; Ambrosini M.T.; Capozzi R.; Callea V.; Cangialosi C.; Montanaro M.; Catalano L.; Grasso M.; Petti M.C.; Merla M.; Falchi L.; Petrucci M.T.; Caravita T.; Bringhen S.; Corradini P.; Raimondo F.D.I.; Boccadoro M.
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network
2007-01-01 PALUMBO A; FALCO P; CORRADINI P; FALCONE A; DI RAIMONDO F; GIULIANI N; CRIPPA C; CICCONE G; OMEDÈ P; AMBROSINI MT; GAY F; BRINGHEN S; MUSTO P; FOÀ R; KNIGHT R; ZELDIS JB; BOCCADORO M; PETRUCCI MT; GIMEMA--ITALIAN MULTIPLE MYELOMA NETWORK
Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy
2007-01-01 PALUMBO A; BRINGHEN S; FALCO P; CAVALLO F; AMBROSINI MT; AVONTO I; GAY F; CARAVITA T; BRUNO B; BOCCADORO M
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients.
2007-01-01 Palumbo A; Bringhen S; Petrucci MT; Falcone A; Liberati AM; Lauta VM; Grasso M; Montanaro M; Pisani F; Caravita T; Cangialosi C; Pregno P; Nozza A; Calabrese E; Gay F; Cavallo F; Omedè P; Musto P; Foà R; Boccadoro M
Efficacy and safety of bortezomib in patients with plasma cell leukemia
2007-01-01 MUSTO P; ROSSINI F; GAY F; PITINI V; GUGLIELMELLI T; D'ARENA G; FERRARA F; FILARDI N; GUARIGLIA R; PALUMBO A
Melphalan and its role in the management of patients with multiple myeloma
2007-01-01 FALCO P; BRINGHEN S; AVONTO I; GAY F; MORABITO F; BOCCADORO M; PALUMBO A
The AKT/mTOR/P70S6K/4EB-P1 Signaling Pathway Is Activated in a Subset of Multiple Myeloma Patients and Correlates with High Serum Levels of Beta 2-Microglobulin.
2008-01-01 T. Guglielmelli;S. Cappia;E. Giugliano;R. Merlini;E. Bacillo;F. Gay;P. Berchialla;D. Gregori;M. Papotti;A. Palumbo;G. Saglio
Gammopatie monoclonali
2008-01-01 Mario Boccadoro, Francesca Gay, Alessandra Larocca, Valeria Magarotto, Antonio Palumbo
Thalidomide for treatment of multiple myeloma: 10 years later
2008-01-01 Palumbo A; Facon T; Sonneveld P; Blade J; Offidani M; Gay F; Moreau P; Waage A; Spencer A; Ludwig H; Boccadoro M; Harousseau JL
From cell biology to therapy: Lenalidomide in untreated multiple myeloma
2008-01-01 Palumbo A.; Falco P.; Gay F.; Magarotto V.; Patriarca F.; Nozzoli C.; Boccadoro M.
Update on recent developments for patients with newly diagnosed multiple myeloma
2008-01-01 Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M.
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
2008-01-01 Montefusco V; Gay F; Spina F; Miceli R; Maniezzo M; Teresa Ambrosini M; Farina L; Piva S; Palumbo A; Boccadoro M; Corradini P.
Oral melphalan, prednisone,and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
2008-01-01 Palumbo A; Bringhen S; Liberati AM; Caravita T; Falcone A; Callea V; Montanaro M; Ria R; Capaldi A; Zambello R; Benevolo G; Derudas D; Dore F; Cavallo F; Gay F; Falco P; Ciccone G; Musto P; Cavo M; Boccadoro M
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
2008-01-01 Palumbo A; Gay F; Bringhen S; Falcone A; Pescosta N; Callea V; Caravita T; Morabito F; Magarotto V; Ruggeri M; Avonto I; Musto P; Cascavilla N; Bruno B; Boccadoro M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma. | 2005 | Palumbo A; Bringhen S; Musto P; Caravita T; Capozzi R; Callea V; Cangialosi C; Montanaro M; Catalano L; Grasso M; Petti MC; Merla M; Falchi L; Omedè P; Ceccarelli M; Ambrosini MT; Avonto I; Gay F; Falco P; Boccadoro M | |
| VelcadeTM Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma. | 2005 | Palumbo A; Ambrosini MT; Pregno P; Pescosta N; Callea V; Cangialosi C; Caravita T; Morabito F; Omedè P; Gay F; Avonto I; Falco P; Bringhen S; Boccadoro M | |
| Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma. | 2005 | Palumbo A; Falco P; Musto P; Corradini P; Di Raimondo R; Rossi G; Giuliani N; Morabito F; Luraschi A; Falcone A; Omedè P; Gay F; Avonto I; Ambrosini MT; Bringhen S; Zeldis J; Knight R; Boccadoro M; Petrucci MT | |
| Time to First Progression, but Not B2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy. | 2006 | Antonio Palumbo; Sara Bringhen; Patrizia Falco; Cecilia Rus; Federica Cavallo; Maria Teresa Ambrosini; Ilaria Avonto; Francesca Gay; Gabriele Gallone; Tommaso Caravita; Benedetto Bruno; and Mario Boccadoro | |
| Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma | 2006 | PALUMBO A; AVONTO I; BRUNO B; FALCONE A; SCALZULLI PR; AMBROSINI MT; BRINGHEN S; GAY F; RUS C; CAVALLO F; FALCO P; MASSAIA M; MUSTO P; BOCCADORO M | |
| INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA | 2006 | P. Musto; I. Avonto; P.R. Scalzulli; B. Bruno; A. Falcone; M.T. Ambrosini; S. Bringhen; F. Gay; C. Rus; F. Cavallo; P. Falco; M. Massaia; M. Boccadoro; A. Palumbo | |
| New treatment strategies for elderly myeloma patients | 2006 | Palumbo A.; Falco P.; Musto P.; Rossi G.; Giuliani N.; Morabito F.; Falcone A.; Gay F.; Avonto I.; Ambrosini M.T.; Capozzi R.; Callea V.; Cangialosi C.; Montanaro M.; Catalano L.; Grasso M.; Petti M.C.; Merla M.; Falchi L.; Petrucci M.T.; Caravita T.; Bringhen S.; Corradini P.; Raimondo F.D.I.; Boccadoro M. | |
| Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network | 2007 | PALUMBO A; FALCO P; CORRADINI P; FALCONE A; DI RAIMONDO F; GIULIANI N; CRIPPA C; CICCONE G; OMEDÈ P; AMBROSINI MT; GAY F; BRINGHEN S; MUSTO P; FOÀ R; KNIGHT R; ZELDIS JB; BOCCADORO M; PETRUCCI MT; GIMEMA--ITALIAN MULTIPLE MYELOMA NETWORK | |
| Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy | 2007 | PALUMBO A; BRINGHEN S; FALCO P; CAVALLO F; AMBROSINI MT; AVONTO I; GAY F; CARAVITA T; BRUNO B; BOCCADORO M | |
| A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (Mel200) Versus Melphalan 100 mg/m2 (Mel100) in Newly Diagnosed Myeloma Patients. | 2007 | Palumbo A; Bringhen S; Petrucci MT; Falcone A; Liberati AM; Lauta VM; Grasso M; Montanaro M; Pisani F; Caravita T; Cangialosi C; Pregno P; Nozza A; Calabrese E; Gay F; Cavallo F; Omedè P; Musto P; Foà R; Boccadoro M | |
| Efficacy and safety of bortezomib in patients with plasma cell leukemia | 2007 | MUSTO P; ROSSINI F; GAY F; PITINI V; GUGLIELMELLI T; D'ARENA G; FERRARA F; FILARDI N; GUARIGLIA R; PALUMBO A | |
| Melphalan and its role in the management of patients with multiple myeloma | 2007 | FALCO P; BRINGHEN S; AVONTO I; GAY F; MORABITO F; BOCCADORO M; PALUMBO A | |
| The AKT/mTOR/P70S6K/4EB-P1 Signaling Pathway Is Activated in a Subset of Multiple Myeloma Patients and Correlates with High Serum Levels of Beta 2-Microglobulin. | 2008 | T. Guglielmelli;S. Cappia;E. Giugliano;R. Merlini;E. Bacillo;F. Gay;P. Berchialla;D. Gregori;M. Papotti;A. Palumbo;G. Saglio | |
| Gammopatie monoclonali | 2008 | Mario Boccadoro, Francesca Gay, Alessandra Larocca, Valeria Magarotto, Antonio Palumbo | |
| Thalidomide for treatment of multiple myeloma: 10 years later | 2008 | Palumbo A; Facon T; Sonneveld P; Blade J; Offidani M; Gay F; Moreau P; Waage A; Spencer A; Ludwig H; Boccadoro M; Harousseau JL | |
| From cell biology to therapy: Lenalidomide in untreated multiple myeloma | 2008 | Palumbo A.; Falco P.; Gay F.; Magarotto V.; Patriarca F.; Nozzoli C.; Boccadoro M. | |
| Update on recent developments for patients with newly diagnosed multiple myeloma | 2008 | Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M. | |
| Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates | 2008 | Montefusco V; Gay F; Spina F; Miceli R; Maniezzo M; Teresa Ambrosini M; Farina L; Piva S; Palumbo A; Boccadoro M; Corradini P. | |
| Oral melphalan, prednisone,and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial | 2008 | Palumbo A; Bringhen S; Liberati AM; Caravita T; Falcone A; Callea V; Montanaro M; Ria R; Capaldi A; Zambello R; Benevolo G; Derudas D; Dore F; Cavallo F; Gay F; Falco P; Ciccone G; Musto P; Cavo M; Boccadoro M | |
| Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma | 2008 | Palumbo A; Gay F; Bringhen S; Falcone A; Pescosta N; Callea V; Caravita T; Morabito F; Magarotto V; Ruggeri M; Avonto I; Musto P; Cascavilla N; Bruno B; Boccadoro M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile